Joseph Geradts

Dr. Geradts' primary research focus is on the molecular pathology of breast cancer. His laboratory uses genomic profiling strategies to identify novel candidate breast cancer genes. Dr. Geradts is also interested in biomarker development. He directs the Tissue Core of Duke's Breast Cancer SPORE and collaborates on numerous breast cancer related research projects with other investigators at Duke and elsewhere.

Current Appointments & Affiliations

Adjunct Professor in the Department of Pathology · 2015 - Present Pathology, Clinical Science Departments

In the News

Published December 2, 2013

Duke study: Many breast cancers may be linked with cholesterol byproduct

View All News

Recent Publications

Patch Based Analysis with Machine Learning to Aid Breast Cancer Recurrence Prediction

Conference Communications in Computer and Information Science · January 1, 2026 Since the introduction of whole slide scanners, machine learning research has become a popular area of interest in digital pathology. Many studies have attempted to use machine learning to aid pathology tasks such as breast cancer diagnosis and metastasis ... Full text Cite

Spatially Discontinuous Mutation Topographies in Ductal Carcinoma In Situ Reveal Noncompetitive Growth Dynamics.

Journal Article Cancer Res · December 15, 2025 UNLABELLED: Preinvasive breast cancer, or ductal carcinoma in situ (DCIS), shares many morphologic and genomic features with invasive breast cancer, yet most DCIS tumors remain indolent over decades. In this study, we performed spatial analyses of somatic ... Full text Link to item Cite

Comparative study of intra- and inter-observer variability in manual scoring of HER2 immunohistochemical stains on glass slides versus paired digital images with emphasis on the low end of the expression spectrum.

Journal Article Hum Pathol · July 2025 With the advent of new therapeutic agents showing efficacy in human breast cancers with low levels of the HER2 oncoprotein, it has become important for pathologists to accurately categorize HER2 expression at the low end of the spectrum. At the same time, ... Full text Link to item Cite

View All Publications

Recent Grants

Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy

ResearchCollaborator · Awarded by Department of Defense · 2012 - 2022

Detection and Elimination of Oncogenic Signaling Networks in Pre-malignant and Malignant Cells with Magnetic Resonance Imaging

ResearchCo Investigator · Awarded by Department of Defense · 2012 - 2022

A Molecular Framework for Understanding DCIS

ResearchCo Investigator · Awarded by Department of Defense · 2014 - 2022

View All Grants

Education, Training & Certifications

The University of Chicago · 1987 M.D.

University of California, Berkeley · 1984 M.A.